Terran

Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

Retrieved on: 
Thursday, April 21, 2022

NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.

Key Points: 
  • NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
  • These therapeutics generated 4 Investigational New Drug(IND) applicationsand over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.
  • Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Evergreen & Oak Launches to be a Results-Driven Public Relations and Marketing Partner for Brands

Retrieved on: 
Wednesday, March 30, 2022

RALEIGH, N.C., March 30, 2022 (GLOBE NEWSWIRE) -- Evergreen & Oak , the results-driven PR and marketing agency where strategy meets execution, launched today.

Key Points: 
  • RALEIGH, N.C., March 30, 2022 (GLOBE NEWSWIRE) -- Evergreen & Oak , the results-driven PR and marketing agency where strategy meets execution, launched today.
  • Evergreen & Oaks client roster includes several innovators in the adtech/martech space including Good-Loop, Vibrant Media, Media Tradecraft, Upflowy and more.
  • Evergreen & Oak is a nimble partner who understands our business, said Erik Requidan, CEO and founder of Media Tradecraft.
  • This experience allows Evergreen & Oak to decipher a brands key differentiators and turn them into compelling stories that align with reporters key interests.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences announces acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals

Retrieved on: 
Friday, March 11, 2022

NEW YORK, March 11, 2022 /PRNewswire/ --Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert's CNS therapeutics and accompanying intellectual property.

Key Points: 
  • NEW YORK, March 11, 2022 /PRNewswire/ --Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert's CNS therapeutics and accompanying intellectual property.
  • Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
  • With this acquisition from Concert, we get even closer to our goal," stated Dr. SamClark, Chief Executive Officer at Terran.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences announces acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals

Retrieved on: 
Friday, March 11, 2022

NEW YORK, March 11, 2022 /PRNewswire/ --Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert's CNS therapeutics and accompanying intellectual property.

Key Points: 
  • NEW YORK, March 11, 2022 /PRNewswire/ --Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert's CNS therapeutics and accompanying intellectual property.
  • Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
  • With this acquisition from Concert, we get even closer to our goal," stated Dr. SamClark, Chief Executive Officer at Terran.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space

Retrieved on: 
Tuesday, March 8, 2022

With this transaction, Terran further expands their broad pipeline of promising clinical stage CNS therapeutics and technologies.

Key Points: 
  • With this transaction, Terran further expands their broad pipeline of promising clinical stage CNS therapeutics and technologies.
  • This intellectual property and data will also complement Terran's current portfolio of over 150 patents covering new compounds and applications in the psychedelic therapeutic space.
  • We look forward to advancing these assets to help patients suffering from devastating neuropsychiatric illnesses."
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space

Retrieved on: 
Tuesday, March 8, 2022

With this transaction, Terran further expands their broad pipeline of promising clinical stage CNS therapeutics and technologies.

Key Points: 
  • With this transaction, Terran further expands their broad pipeline of promising clinical stage CNS therapeutics and technologies.
  • This intellectual property and data will also complement Terran's current portfolio of over 150 patents covering new compounds and applications in the psychedelic therapeutic space.
  • We look forward to advancing these assets to help patients suffering from devastating neuropsychiatric illnesses."
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Orbital to Build Microsatellite Program

Retrieved on: 
Thursday, February 17, 2022

BOCA RATON, Fla., Feb. 17, 2022 /PRNewswire/ -- Small-satellite pioneer Terran Orbital Corporation ("Terran Orbital") was awarded a contract by Lockheed Martin Aeronautics to provide three microsatellite class satellites, launch procurement, integration, and operations in support of product demonstration.

Key Points: 
  • BOCA RATON, Fla., Feb. 17, 2022 /PRNewswire/ -- Small-satellite pioneer Terran Orbital Corporation ("Terran Orbital") was awarded a contract by Lockheed Martin Aeronautics to provide three microsatellite class satellites, launch procurement, integration, and operations in support of product demonstration.
  • "At Terran Orbital we pride ourselves on creating high quality, cost-effective satellite solutions that surpass the customers' needs," said Matt Gann, Senior Vice President of Programs at Terran Orbital.
  • Terran Orbital has previously announced that it entered in a business combination agreement with Tailwind Two Acquisition Corp. (NYSE: TWNT), ("Tailwind Two"), a special purpose acquisition company (SPAC), pursuant to which Terran Orbital will combine with Tailwind Two.
  • This press release includes certain forward-looking statements, estimates, and projections provided by Terran Orbital that reflect management's views regarding the anticipated future financial and operating performance of Terran Orbital.

Governor Ron DeSantis Announces Terran Orbital will Invest $300 Million in Florida to Construct the World's Largest, State-of-the-Art, Commercial Spacecraft Facility

Retrieved on: 
Monday, September 27, 2021

The 660,000 square foot facility will feature a campus-based AI controlled supply chain enabling Terran Orbital to uphold its renowned reputation for mission assurance and customer satisfaction.

Key Points: 
  • The 660,000 square foot facility will feature a campus-based AI controlled supply chain enabling Terran Orbital to uphold its renowned reputation for mission assurance and customer satisfaction.
  • In addition, the facility will utilize augmented and assisted workforce product lines to produce a vast array of complex electronic and mechanical devices.
  • "I am excited to announce that Terran Orbital will be investing $300 million in the Space Coast to build the largest satellite manufacturing facility in the world," said Governor DeSantis.
  • www.terranorbital.com
    About Space Florida: Space Florida was created to strengthen Florida's position as the global leader in aerospace research, investment, exploration and commerce.